MedaSorb to file IDE for drug detoxification technology

By Lisa Kerner

Charlotte, N.C., Sept. 19 - MedaSorb Technologies, Inc. said it intends to file an Investigational Device Exemption with the Food and Drug Administration by the end of the year for CytoSorb's Drug Detoxification indication.

The company believes CytoSorb's adsorbent bead technology for drug detoxification is superior to current charcoal filter technology for removing drugs toxins from the blood stream in overdose traumas.

MedaSorb said it is also progressing in its sepsis treatment indication.

"The company has sufficient resources to commence the Sepsis clinical trails, and we are excited about moving forward on both indications," president and chief executive officer Al Kraus said in a news release.

MedaSorb is a medical device company based in Monmouth Junction, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.